Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
An announcement from Alcon ( (CH:ALC) ) is now available.
On August 19, 2025, Alcon reported its second-quarter 2025 financial results, highlighting a 4% increase in sales compared to the previous year, reaching $2.6 billion. The company launched Tryptyr, a new treatment for dry eye disease, and announced the acquisition of STAAR Surgical to enhance its offerings in myopia correction. These strategic moves aim to strengthen Alcon’s market position and expand its product portfolio, potentially benefiting shareholders and patients alike.
The most recent analyst rating on (CH:ALC) stock is a Buy with a CHF79.00 price target. To see the full list of analyst forecasts on Alcon stock, see the CH:ALC Stock Forecast page.
More about Alcon
Alcon Inc. is a global leader in eye care, primarily focusing on surgical and vision care products. The company is known for its innovative treatments and devices aimed at addressing various eye conditions, including myopia and dry eye disease.
Average Trading Volume: 961,949
Technical Sentiment Signal: Hold
Current Market Cap: CHF35.25B
Learn more about ALC stock on TipRanks’ Stock Analysis page.